In patients with type 2 diabetes, silent cerebral infarction (SCI), small areas of brain damage caused by injury to small blood vessels, signals an increased risk of progressive kidney disease and kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).
If SCI is present in the brain, it could be an indicator that small-vessel damage is present in the kidneys as well, suggests the new study by Takashi Uzu, MD (Shiga University School of Medicine, Otsu, Japan). Uzu said in a statement that "Silent cerebral infarction may be a new marker to identify patients who are risk for declining kidney function."
The study included 608 patients with type 2 diabetes, all initially free of symptomatic stroke, heart disease, or kidney disease (overt proteinuria or renal dysfunction). On magnetic resonance imaging (MRI) scans of the brain, 177 of the patients (29%) had SCI subtle areas of brain damage caused by disease of the brain blood vessels, but not severe enough to cause overt symptoms of stroke.
At long-term follow-up, diabetic patients with SCI had higher risks of progressive kidney disease. Compared to those with normal brain MRI scans, patients with SCI were about 2.5 times more likely to die or develop end-stage kidney disease. Their risk of declining kidney function or dialysis was nearly five times higher.
The new study shows that diabetic patients with subtle brain damage detected on MRI scans are more likely to develop serious kidney disease, independent of microalbuminuria.
The study had some risk of bias related to patient selection. Also, although most of the patients with SCI had multiple small areas of brain damage, the study did not exclude patients with relatively large areas of brain damage. "Therefore, not only small vessel disease but also relatively large vessel disease might have affected the progression of kidney disease in our patients," said Uzu.
The American Society of Nephrology (ASN) does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects.
[Source: American Society of Nephrology]